• PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberc...

  2026-04-01

  PA-824, a bicyclic nitroimidazole derivative, is a potent anti-tuberculosis drug candidate with activity against drug-resistant Mycobacterium tuberculosis. It inhibits ketomycolate biosynthesis and releases intracellular nitric oxide, providing bactericidal effects and supporting advanced tuberculosis research.

• Mitomycin C: Antitumor Antibiotic for Advanced Cancer Res...

  2026-04-01

  Mitomycin C stands apart as a potent DNA synthesis inhibitor and apoptosis inducer, enabling cancer researchers to dissect p53-independent pathways and enhance TRAIL-induced cell death. This guide delivers actionable workflows, optimization tips, and comparative insights for leveraging Mitomycin C from APExBIO in high-impact oncology studies.

• SU 5402: Precision FGFR/VEGFR/PDGFR Kinase Inhibitor for ...

  2026-03-31

  SU 5402 is a potent, multi-targeted receptor tyrosine kinase inhibitor used in cancer biology and neuronal model studies. Its nanomolar potency enables reliable blockade of FGFR3, VEGFR2, and PDGFRβ signaling, facilitating high-fidelity pathway dissection and robust apoptosis/cell cycle assays.

• BX795: Potent ATP-Competitive PDK1/TBK1/IKKε Inhibitor fo...

  2026-03-31

  BX795 is a highly selective, ATP-competitive inhibitor of PDK1, TBK1, and IKKε, enabling precise dissection of PI3K/Akt/mTOR and type I interferon signaling pathways. This compound demonstrates nanomolar potency in kinase assays and micromolar inhibition of tumor cell growth, making it an indispensable tool for cancer, immune, and antiviral research. APExBIO provides BX795 (A8222) as a rigorously characterized reagent for advanced translational workflows.

• SU 5402: Potent VEGFR2/FGFR/PDGFR Inhibitor for Cancer an...

  2026-03-30

  SU 5402 is a highly selective receptor tyrosine kinase inhibitor used in cancer biology and multiple myeloma research. Its nanomolar potency against VEGFR2, FGFR1, and PDGFRβ, and its ability to induce cell cycle arrest and apoptosis, make it a gold-standard tool for dissecting RTK signaling pathways.

• PA-824: Breakthrough Mechanisms and Next-Gen Strategies f...

  2026-03-30

  Explore the advanced antimycobacterial action of PA-824, a leading bicyclic nitroimidazole derivative, and its unique role in overcoming drug-resistant tuberculosis. Delve into novel mechanistic insights and future applications that distinguish this cornerstone article from existing resources.

• Estradiol Benzoate: High-Purity Estrogen Receptor Alpha A...

  2026-03-29

  Estradiol Benzoate is a synthetic estradiol analog and potent estrogen receptor alpha (ERα) agonist, optimized for precise hormone receptor signaling research. This dossier details its molecular properties, validated bioactivity, and technical benchmarks, providing researchers with reliable, verifiable data for reproducible assays.

• SU5416 (Semaxanib) VEGFR2 Inhibitor: Mechanistic Insight ...

  2026-03-28

  This thought-leadership article unpacks the dual mechanistic roles of SU5416 (Semaxanib)—as a selective VEGFR2 inhibitor and aryl hydrocarbon receptor (AHR) agonist—within the evolving landscape of cancer, vascular, and immune modulation research. Integrating mechanistic rationale, preclinical evidence, and translational guidance, it positions SU5416 as an indispensable tool for next-generation biomarker discovery and disease modeling, referencing both emerging serum proteomics (e.g., HGFA in PAH) and best practices for experimental design. The piece also connects researchers to further in-depth resources and articulates how this analysis pushes beyond conventional product coverage.

• PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberc...

  2026-03-27

  PA-824 stands out as a high-purity bicyclic nitroimidazole derivative, empowering tuberculosis researchers to tackle both drug-sensitive and drug-resistant Mycobacterium tuberculosis with precision. Its unique dual-action mechanism and robust workflow compatibility accelerate MIC determinations, synergy studies, and next-generation drug development.

• Mitomycin C: Advanced Insights in DNA Crosslinking and Ap...

  2026-03-27

  Explore the multifaceted role of Mitomycin C as an antitumor antibiotic, DNA synthesis inhibitor, and apoptosis inducer in cancer research. This article delivers a deep dive into mechanistic pathways, p53-independent apoptosis, and cutting-edge applications in colon and bladder cancer models—offering new perspectives and research strategies.

• DiscoveryProbe™ FDA-approved Drug Library: Transforming D...

  2026-03-26

  Explore the DiscoveryProbe™ FDA-approved Drug Library—a comprehensive FDA-approved bioactive compound library—for advanced drug repositioning and pharmacological target identification. This article reveals unique mechanistic insights and practical strategies, including reference-driven applications in muscle biology and beyond.

• Scenario-Driven Guidance for Reliable Cell Assays Using B...

  2026-03-26

  This article delivers an expert, scenario-based roadmap for employing BX795 (SKU A8222) in cell viability, proliferation, and cytotoxicity assays. Drawing on published data and real laboratory challenges, we explore how BX795’s selectivity and dual targeting of PDK1, TBK1, and IKKε help researchers achieve reproducible, interpretable results. Practical advice is integrated throughout, emphasizing when and why this small molecule inhibitor outperforms less-characterized alternatives.

• SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Angiog...

  2026-03-25

  SU5416 (Semaxanib) acts as a potent and selective VEGFR2 tyrosine kinase inhibitor, offering robust angiogenesis inhibition and immune pathway modulation for cancer research. Its high selectivity, reproducible in vivo efficacy, and dual targeting of vascular and immune mechanisms distinguish it as a versatile tool for translational studies.

• Enhancing Cell Assay Reliability: Scenario-Driven Insight...

  2026-03-25

  Explore how SU 5402 (SKU A3843) from APExBIO addresses real-world challenges in cell viability, cytotoxicity, and signal transduction assays. This scenario-based guide delivers evidence-backed strategies for optimizing data reproducibility and workflow efficiency in cancer and neurobiology research, with practical Q&A supported by published literature and direct product application.

• DiscoveryProbe FDA-approved Drug Library: Optimizing High...

  2026-03-24

  The DiscoveryProbe™ FDA-approved Drug Library empowers scientists with a rigorously curated, ready-to-screen collection of 2,320 clinically approved compounds, accelerating drug repositioning and pharmacological target identification. Its robust DMSO-based format, flexible plate options, and proven performance in diverse assays make it an indispensable tool for high-throughput and high-content screening workflows.

16789 records 1/1120 page Next 12345 下5页 Last page